Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 130

1.

Randomized Trial of Verubecestat for Prodromal Alzheimer's Disease.

Egan MF, Kost J, Voss T, Mukai Y, Aisen PS, Cummings JL, Tariot PN, Vellas B, van Dyck CH, Boada M, Zhang Y, Li W, Furtek C, Mahoney E, Harper Mozley L, Mo Y, Sur C, Michelson D.

N Engl J Med. 2019 Apr 11;380(15):1408-1420. doi: 10.1056/NEJMoa1812840.

PMID:
30970186
2.

Convergence of placenta biology and genetic risk for schizophrenia.

Ursini G, Punzi G, Chen Q, Marenco S, Robinson JF, Porcelli A, Hamilton EG, Mitjans M, Maddalena G, Begemann M, Seidel J, Yanamori H, Jaffe AE, Berman KF, Egan MF, Straub RE, Colantuoni C, Blasi G, Hashimoto R, Rujescu D, Ehrenreich H, Bertolino A, Weinberger DR.

Nat Med. 2018 Jun;24(6):792-801. doi: 10.1038/s41591-018-0021-y. Epub 2018 May 28.

PMID:
29808008
3.

Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer's Disease.

Egan MF, Kost J, Tariot PN, Aisen PS, Cummings JL, Vellas B, Sur C, Mukai Y, Voss T, Furtek C, Mahoney E, Harper Mozley L, Vandenberghe R, Mo Y, Michelson D.

N Engl J Med. 2018 May 3;378(18):1691-1703. doi: 10.1056/NEJMoa1706441.

4.

A multinational study distinguishing Alzheimer's and healthy patients using cerebrospinal fluid tau/Aβ42 cutoff with concordance to amyloid positron emission tomography imaging.

Mo Y, Stromswold J, Wilson K, Holder D, Sur C, Laterza O, Savage MJ, Struyk A, Scheltens P, Teunissen CE, Burke J, Macaulay SL, Bråthen G, Sando SB, White LR, Weiss C, Cowes A, Bush MM, DeSilva G, Darby DG, Rainey-Smith SR, Surls J, Sagini E, Tanen M, Altman A, Luthman J, Egan MF.

Alzheimers Dement (Amst). 2017 Mar 6;6:201-209. doi: 10.1016/j.dadm.2017.02.004. eCollection 2017.

5.

Translational and Early Phase Strategies for Treatment Development: Report of ISCTM Autumn 2013 Symposium.

Young JW, Potter WZ, Riley S, Groeneveld GJ, Kinon BJ, Egan MF, Feltner DE.

Innov Clin Neurosci. 2015 Mar-Apr;12(3-4):5S-10S.

6.

Perceptual Category Judgment Deficits are Related to Prefrontal Decision Making Abnormalities in Schizophrenia.

Weickert TW, Terrazas A, Bigelow LB, Apud JA, Egan MF, Weinberger DR.

Front Psychiatry. 2014 Jan 6;4:184. doi: 10.3389/fpsyt.2013.00184. eCollection 2014 Jan 6.

7.

Dopaminergic therapy removal differentially effects learning in schizophrenia and Parkinson's disease.

Weickert TW, Mattay VS, Das S, Bigelow LB, Apud JA, Egan MF, Weinberger DR, Goldberg TE.

Schizophr Res. 2013 Sep;149(1-3):162-6. doi: 10.1016/j.schres.2013.06.028. Epub 2013 Jul 3.

8.

Randomized controlled study of the T-type calcium channel antagonist MK-8998 for the treatment of acute psychosis in patients with schizophrenia.

Egan MF, Zhao X, Smith A, Troyer MD, Uebele VN, Pidkorytov V, Cox K, Murphy M, Snavely D, Lines C, Michelson D.

Hum Psychopharmacol. 2013 Mar;28(2):124-33. doi: 10.1002/hup.2289.

PMID:
23532746
9.

Absence of evidence for bornavirus infection in schizophrenia, bipolar disorder and major depressive disorder.

Hornig M, Briese T, Licinio J, Khabbaz RF, Altshuler LL, Potkin SG, Schwemmle M, Siemetzki U, Mintz J, Honkavuori K, Kraemer HC, Egan MF, Whybrow PC, Bunney WE, Lipkin WI.

Mol Psychiatry. 2012 May;17(5):486-93. doi: 10.1038/mp.2011.179. Epub 2012 Jan 31.

10.

Magnitude of impact of executive functioning and IQ on episodic memory in Schizophrenia.

Kopald BE, Mirra KM, Egan MF, Weinberger DR, Goldberg TE.

Biol Psychiatry. 2012 Mar 15;71(6):545-51. doi: 10.1016/j.biopsych.2011.11.021. Epub 2012 Jan 23.

PMID:
22265665
11.

Relative risk of probabilistic category learning deficits in patients with schizophrenia and their siblings.

Weickert TW, Goldberg TE, Egan MF, Apud JA, Meeter M, Myers CE, Gluck MA, Weinberger DR.

Biol Psychiatry. 2010 May 15;67(10):948-55. doi: 10.1016/j.biopsych.2009.12.027. Epub 2010 Feb 20.

12.

A primate-specific, brain isoform of KCNH2 affects cortical physiology, cognition, neuronal repolarization and risk of schizophrenia.

Huffaker SJ, Chen J, Nicodemus KK, Sambataro F, Yang F, Mattay V, Lipska BK, Hyde TM, Song J, Rujescu D, Giegling I, Mayilyan K, Proust MJ, Soghoyan A, Caforio G, Callicott JH, Bertolino A, Meyer-Lindenberg A, Chang J, Ji Y, Egan MF, Goldberg TE, Kleinman JE, Lu B, Weinberger DR.

Nat Med. 2009 May;15(5):509-18. doi: 10.1038/nm.1962. Epub 2009 May 3.

13.

The Premorbid Adjustment Scale as a measure of developmental compromise in patients with schizophrenia and their healthy siblings.

Shapiro DI, Marenco S, Spoor EH, Egan MF, Weinberger DR, Gold JM.

Schizophr Res. 2009 Jul;112(1-3):136-42. doi: 10.1016/j.schres.2009.04.007. Epub 2009 May 1.

14.

Neural correlates of probabilistic category learning in patients with schizophrenia.

Weickert TW, Goldberg TE, Callicott JH, Chen Q, Apud JA, Das S, Zoltick BJ, Egan MF, Meeter M, Myers C, Gluck MA, Weinberger DR, Mattay VS.

J Neurosci. 2009 Jan 28;29(4):1244-54. doi: 10.1523/JNEUROSCI.4341-08.2009.

15.

Functional polymorphisms in PRODH are associated with risk and protection for schizophrenia and fronto-striatal structure and function.

Kempf L, Nicodemus KK, Kolachana B, Vakkalanka R, Verchinski BA, Egan MF, Straub RE, Mattay VA, Callicott JH, Weinberger DR, Meyer-Lindenberg A.

PLoS Genet. 2008 Nov;4(11):e1000252. doi: 10.1371/journal.pgen.1000252. Epub 2008 Nov 7.

16.

Enuresis as a premorbid developmental marker of schizophrenia.

Hyde TM, Deep-Soboslay A, Iglesias B, Callicott JH, Gold JM, Meyer-Lindenberg A, Honea RA, Bigelow LB, Egan MF, Emsellem EM, Weinberger DR.

Brain. 2008 Sep;131(Pt 9):2489-98. doi: 10.1093/brain/awn167. Epub 2008 Jul 31.

17.

Verbal and visual memory: characterizing the clinical and intermediate phenotype in schizophrenia.

Skelley SL, Goldberg TE, Egan MF, Weinberger DR, Gold JM.

Schizophr Res. 2008 Oct;105(1-3):78-85. doi: 10.1016/j.schres.2008.05.027. Epub 2008 Jul 10.

PMID:
18617370
18.

Set-shifting ability and schizophrenia: a marker of clinical illness or an intermediate phenotype?

Ceaser AE, Goldberg TE, Egan MF, McMahon RP, Weinberger DR, Gold JM.

Biol Psychiatry. 2008 Nov 1;64(9):782-8. doi: 10.1016/j.biopsych.2008.05.009. Epub 2008 Jul 2.

19.

The evolutionarily conserved G protein-coupled receptor SREB2/GPR85 influences brain size, behavior, and vulnerability to schizophrenia.

Matsumoto M, Straub RE, Marenco S, Nicodemus KK, Matsumoto S, Fujikawa A, Miyoshi S, Shobo M, Takahashi S, Yarimizu J, Yuri M, Hiramoto M, Morita S, Yokota H, Sasayama T, Terai K, Yoshino M, Miyake A, Callicott JH, Egan MF, Meyer-Lindenberg A, Kempf L, Honea R, Vakkalanka RK, Takasaki J, Kamohara M, Soga T, Hiyama H, Ishii H, Matsuo A, Nishimura S, Matsuoka N, Kobori M, Matsushime H, Katoh M, Furuichi K, Weinberger DR.

Proc Natl Acad Sci U S A. 2008 Apr 22;105(16):6133-8. doi: 10.1073/pnas.0710717105. Epub 2008 Apr 14.

20.

Evidence of biologic epistasis between BDNF and SLC6A4 and implications for depression.

Pezawas L, Meyer-Lindenberg A, Goldman AL, Verchinski BA, Chen G, Kolachana BS, Egan MF, Mattay VS, Hariri AR, Weinberger DR.

Mol Psychiatry. 2008 Jul;13(7):709-16. doi: 10.1038/mp.2008.32. Epub 2008 Mar 18.

PMID:
18347599
21.

False positives in imaging genetics.

Meyer-Lindenberg A, Nicodemus KK, Egan MF, Callicott JH, Mattay V, Weinberger DR.

Neuroimage. 2008 Apr 1;40(2):655-661. doi: 10.1016/j.neuroimage.2007.11.058. Epub 2007 Dec 15.

PMID:
18201908
22.

Serious obstetric complications interact with hypoxia-regulated/vascular-expression genes to influence schizophrenia risk.

Nicodemus KK, Marenco S, Batten AJ, Vakkalanka R, Egan MF, Straub RE, Weinberger DR.

Mol Psychiatry. 2008 Sep;13(9):873-7. doi: 10.1038/sj.mp.4002153. Epub 2008 Jan 15.

PMID:
18195713
23.

BDNF Val66Met polymorphism significantly affects d' in verbal recognition memory at short and long delays.

Goldberg TE, Iudicello J, Russo C, Elvevåg B, Straub R, Egan MF, Weinberger DR.

Biol Psychol. 2008 Jan;77(1):20-4. Epub 2007 Sep 1.

PMID:
17988784
24.

Allelic variation in GAD1 (GAD67) is associated with schizophrenia and influences cortical function and gene expression.

Straub RE, Lipska BK, Egan MF, Goldberg TE, Callicott JH, Mayhew MB, Vakkalanka RK, Kolachana BS, Kleinman JE, Weinberger DR.

Mol Psychiatry. 2007 Sep;12(9):854-69. Epub 2007 May 1.

PMID:
17767149
25.

Genetic variation in catechol-O-methyltransferase: effects on working memory in schizophrenic patients, their siblings, and healthy controls.

Diaz-Asper CM, Goldberg TE, Kolachana BS, Straub RE, Egan MF, Weinberger DR.

Biol Psychiatry. 2008 Jan 1;63(1):72-9. Epub 2007 Aug 20.

26.

Is gray matter volume an intermediate phenotype for schizophrenia? A voxel-based morphometry study of patients with schizophrenia and their healthy siblings.

Honea RA, Meyer-Lindenberg A, Hobbs KB, Pezawas L, Mattay VS, Egan MF, Verchinski B, Passingham RE, Weinberger DR, Callicott JH.

Biol Psychiatry. 2008 Mar 1;63(5):465-74. Epub 2007 Aug 8.

27.

Frontal release signs and cognition in people with schizophrenia, their siblings and healthy controls.

Hyde TM, Goldberg TE, Egan MF, Lener MC, Weinberger DR.

Br J Psychiatry. 2007 Aug;191:120-5.

PMID:
17666495
28.

Epistasis between catechol-O-methyltransferase and type II metabotropic glutamate receptor 3 genes on working memory brain function.

Tan HY, Chen Q, Sust S, Buckholtz JW, Meyers JD, Egan MF, Mattay VS, Meyer-Lindenberg A, Weinberger DR, Callicott JH.

Proc Natl Acad Sci U S A. 2007 Jul 24;104(30):12536-41. Epub 2007 Jul 16.

29.

Factor analysis of neurocognitive tests in a large sample of schizophrenic probands, their siblings, and healthy controls.

Genderson MR, Dickinson D, Diaz-Asper CM, Egan MF, Weinberger DR, Goldberg TE.

Schizophr Res. 2007 Aug;94(1-3):231-9. Epub 2007 Jun 13.

PMID:
17570645
30.

Genetic variation in MAOA modulates ventromedial prefrontal circuitry mediating individual differences in human personality.

Buckholtz JW, Callicott JH, Kolachana B, Hariri AR, Goldberg TE, Genderson M, Egan MF, Mattay VS, Weinberger DR, Meyer-Lindenberg A.

Mol Psychiatry. 2008 Mar;13(3):313-24. Epub 2007 May 22.

PMID:
17519928
31.

Neuregulin1-induced cell migration is impaired in schizophrenia: association with neuregulin1 and catechol-o-methyltransferase gene polymorphisms.

Sei Y, Ren-Patterson R, Li Z, Tunbridge EM, Egan MF, Kolachana BS, Weinberger DR.

Mol Psychiatry. 2007 Oct;12(10):946-57. Epub 2007 Apr 17.

PMID:
17440436
32.

Allelic variation in RGS4 impacts functional and structural connectivity in the human brain.

Buckholtz JW, Meyer-Lindenberg A, Honea RA, Straub RE, Pezawas L, Egan MF, Vakkalanka R, Kolachana B, Verchinski BA, Sust S, Mattay VS, Weinberger DR, Callicott JH.

J Neurosci. 2007 Feb 14;27(7):1584-93.

33.

Genetic evidence implicating DARPP-32 in human frontostriatal structure, function, and cognition.

Meyer-Lindenberg A, Straub RE, Lipska BK, Verchinski BA, Goldberg T, Callicott JH, Egan MF, Huffaker SS, Mattay VS, Kolachana B, Kleinman JE, Weinberger DR.

J Clin Invest. 2007 Mar;117(3):672-82. Epub 2007 Feb 8.

34.

Catechol O-methyltransferase val158met genotype and neural mechanisms related to affective arousal and regulation.

Drabant EM, Hariri AR, Meyer-Lindenberg A, Munoz KE, Mattay VS, Kolachana BS, Egan MF, Weinberger DR.

Arch Gen Psychiatry. 2006 Dec;63(12):1396-406.

PMID:
17146014
35.

Dysfunctional prefrontal regional specialization and compensation in schizophrenia.

Tan HY, Sust S, Buckholtz JW, Mattay VS, Meyer-Lindenberg A, Egan MF, Weinberger DR, Callicott JH.

Am J Psychiatry. 2006 Nov;163(11):1969-77.

PMID:
17074949
36.

Instability of prefrontal signal processing in schizophrenia.

Winterer G, Musso F, Beckmann C, Mattay V, Egan MF, Jones DW, Callicott JH, Coppola R, Weinberger DR.

Am J Psychiatry. 2006 Nov;163(11):1960-8.

PMID:
17074948
37.

Tolcapone improves cognition and cortical information processing in normal human subjects.

Apud JA, Mattay V, Chen J, Kolachana BS, Callicott JH, Rasetti R, Alce G, Iudicello JE, Akbar N, Egan MF, Goldberg TE, Weinberger DR.

Neuropsychopharmacology. 2007 May;32(5):1011-20. Epub 2006 Oct 25.

38.

Evidence for statistical epistasis between catechol-O-methyltransferase (COMT) and polymorphisms in RGS4, G72 (DAOA), GRM3, and DISC1: influence on risk of schizophrenia.

Nicodemus KK, Kolachana BS, Vakkalanka R, Straub RE, Giegling I, Egan MF, Rujescu D, Weinberger DR.

Hum Genet. 2007 Feb;120(6):889-906. Epub 2006 Sep 28.

PMID:
17006672
39.

Prefrontal electrophysiologic "noise" and catechol-O-methyltransferase genotype in schizophrenia.

Winterer G, Egan MF, Kolachana BS, Goldberg TE, Coppola R, Weinberger DR.

Biol Psychiatry. 2006 Sep 15;60(6):578-84. Epub 2006 May 30.

PMID:
16730334
40.

Evaluation of a susceptibility gene for schizophrenia: genotype based meta-analysis of RGS4 polymorphisms from thirteen independent samples.

Talkowski ME, Seltman H, Bassett AS, Brzustowicz LM, Chen X, Chowdari KV, Collier DA, Cordeiro Q, Corvin AP, Deshpande SN, Egan MF, Gill M, Kendler KS, Kirov G, Heston LL, Levitt P, Lewis DA, Li T, Mirnics K, Morris DW, Norton N, O'Donovan MC, Owen MJ, Richard C, Semwal P, Sobell JL, St Clair D, Straub RE, Thelma BK, Vallada H, Weinberger DR, Williams NM, Wood J, Zhang F, Devlin B, Nimgaonkar VL.

Biol Psychiatry. 2006 Jul 15;60(2):152-62. Epub 2006 Apr 21. Review.

41.

Effect of metabotropic glutamate receptor 3 genotype on N-acetylaspartate measures in the dorsolateral prefrontal cortex.

Marenco S, Steele SU, Egan MF, Goldberg TE, Straub RE, Sharrief AZ, Weinberger DR.

Am J Psychiatry. 2006 Apr;163(4):740-2.

42.

The G72/G30 gene complex and cognitive abnormalities in schizophrenia.

Goldberg TE, Straub RE, Callicott JH, Hariri A, Mattay VS, Bigelow L, Coppola R, Egan MF, Weinberger DR.

Neuropsychopharmacology. 2006 Sep;31(9):2022-32. Epub 2006 Mar 22.

43.
44.

Variation in DISC1 affects hippocampal structure and function and increases risk for schizophrenia.

Callicott JH, Straub RE, Pezawas L, Egan MF, Mattay VS, Hariri AR, Verchinski BA, Meyer-Lindenberg A, Balkissoon R, Kolachana B, Goldberg TE, Weinberger DR.

Proc Natl Acad Sci U S A. 2005 Jun 14;102(24):8627-32. Epub 2005 Jun 6.

45.

Effect of catechol-O-methyltransferase val158met genotype on attentional control.

Blasi G, Mattay VS, Bertolino A, Elvevåg B, Callicott JH, Das S, Kolachana BS, Egan MF, Goldberg TE, Weinberger DR.

J Neurosci. 2005 May 18;25(20):5038-45.

46.

5-HTTLPR polymorphism impacts human cingulate-amygdala interactions: a genetic susceptibility mechanism for depression.

Pezawas L, Meyer-Lindenberg A, Drabant EM, Verchinski BA, Munoz KE, Kolachana BS, Egan MF, Mattay VS, Hariri AR, Weinberger DR.

Nat Neurosci. 2005 Jun;8(6):828-34. Epub 2005 May 8.

PMID:
15880108
47.

Regionally specific disturbance of dorsolateral prefrontal-hippocampal functional connectivity in schizophrenia.

Meyer-Lindenberg AS, Olsen RK, Kohn PD, Brown T, Egan MF, Weinberger DR, Berman KF.

Arch Gen Psychiatry. 2005 Apr;62(4):379-86.

PMID:
15809405
48.

A susceptibility gene for affective disorders and the response of the human amygdala.

Hariri AR, Drabant EM, Munoz KE, Kolachana BS, Mattay VS, Egan MF, Weinberger DR.

Arch Gen Psychiatry. 2005 Feb;62(2):146-52.

PMID:
15699291
49.

Childhood-onset schizophrenia: smooth pursuit eye-tracking dysfunction in family members.

Sporn A, Greenstein D, Gogtay N, Sailer F, Hommer DW, Rawlings R, Nicolson R, Egan MF, Lenane M, Gochman P, Weinberger DR, Rapoport JL.

Schizophr Res. 2005 Mar 1;73(2-3):243-52.

PMID:
15653267
50.

The brain-derived neurotrophic factor val66met polymorphism and variation in human cortical morphology.

Pezawas L, Verchinski BA, Mattay VS, Callicott JH, Kolachana BS, Straub RE, Egan MF, Meyer-Lindenberg A, Weinberger DR.

J Neurosci. 2004 Nov 10;24(45):10099-102.

Supplemental Content

Support Center